Phase 1: SVV-001 for neuroendocrine solid tumors

[Maxone73]

Why not "non neuroendocrine"?? Time will tell! But here is another application of an oncolytic virus...

The Sylvester Comprehensive Cancer Center has launched a clinical trial for high-grade neuroendocrine tumors, a rare and aggressive cancer with limited treatment options beyond chemotherapy.

The trial combines checkpoint inhibitors (nivolumab and ipilimumab) with SVV-001, an oncolytic virus that targets and bursts tumor cells, sparking an immune response. The virus turns “cold” tumors “hot,” making them responsive to immunotherapy, which then amplifies the attack.

Aimed at 36 patients with resistant tumors, the phase 1 study tests safety, dosing, and a biomarker (TEM8) to enhance targeting, offering hope for better outcomes.

prostatewarriors.com/2025/0...